U.S. Secret Service Relaxes Past-Use Cannabis Policy for Applicants
by Mary E.
Israel has been on the must-watch list in terms of cannabis research and medicinal innovation and now they have made headlines for reading a record high of over 60,000 medical cannabis patients. This number of cannabis patients is truly remarkable but with such high numbers, the country is struggling to avoid shortages and to meet the ever-rising demand of cannabis for treatment.
Many may be surprised to find out that cannabis-based medication has been legal in Israel since the late 1990s and the country continues to grow into one of the world’s largest cannabis hubs. The country also possesses the most developed medicinal cannabis system outside of North America. Prior to the year 2019, Israeli citizens accessed their cannabis directly from the few licensed producers and at a fixed cost, regardless of how much cannabis they have required. However, the 2019 cannabis reforms in Israel has led to shortages in supply and many unsatisfied cannabis patients.
Israel’s cannabis reform was imposed by the Ministry of Health’s Medical Cannabis Association (locally referred to as Yakar) and has left vulnerable cannabis patients with problems accessing and affording cannabis treatment. The reform was intended to minimize hurdles related to cannabis treatment, however, has caused quite the opposite.
The main sections of the reform were designated for business and patients. The business portion of the reform outlined licensing procedures for cannabis research, disposal, and transportation while the patient’s portion was to reclassify cannabis into the same category as other medications that can be prescribed. The patient’s portion also states that in order to be eligible, the medicinal cannabis patients must get controlled cannabis products sold in pharmacies, be over 18 years of age, be registered with a specialist physician as well as have a monthly prescription of 40 grams or less.
While the reform appears to be supportive for patients, the implementation has not been going so well and the ones suffering from that are the patients. The patients are experiencing delays in obtaining licenses, inabilities to renew licenses and when they can get access to cannabis, its quality and quantity are worse and less than ever before.
The Israeli news site, The Jerusalem Post, reported that 61.1% of the complaints lodged against Yakar has been found to be valid. It also reported that the Health Ministry “was found to be unjustifiably blocking the use of cannabis in 83% of cases”.
Israel’s cannabis reform, which came into effect on the 1st of April 2020, has outlined new quality standards for the producers which are causing compliance issues with a significant number of businesses. The new criteria for patients having to access cannabis from licensed pharmacies mean that patients are now being charged per gram, as opposed to the previous flat rate. For patients who require a rather large quantity of cannabis, the cost has become too much, especially since Yakar has not introduced or implemented any forms of rebate or reimbursement. The reform legislation allows for the importing of cannabis plants by businesses, of which half a dozen have imported 7 tons from around 12 different countries. While the cannabis consumers claim that the imported goods are superior to those grown in Israel, the cannabis patients report the inconsistent treatment as they acclimatize to the new products, await licenses, and adjust to the increase in cost.
In an interview with Cannatech, two Israeli medical cannabis patients explained that cannabis reform is harming patients through the chain of treatment, availability of targeted trains, the increasing costs, and the invasion of privacy as a result of the licensing process. The Israeli medical cannabis supply gap may continue to widen, even if the current supply jam clears up since the reform allows for the expansion of prescription parameters. Cannabis patients who make use of extracts for consumption will most likely have to apply for a special license, especially if the plant matter in the oil is more than 100 grams. In fact, any patient who needs larger quantities of cannabis, more than 100 grams, will have to jump through flaming hoops of all heights to attain this special license. The CannaTech interview also stated that
“essentially, the sickest patients will benefit the least from the Israeli medical cannabis reform”.
Some patients have even reported experiencing public shaming and are dealing with the same stigma associated with that of a drug addict. Yet, the number of individuals turning to cannabis continues to rise in this cannabis research and development hub. If Yakar’s intention of paving easier access to medicinal cannabis is true, then the supply gap, cost of cannabis to consumers, stigma, and other bumps need to be worked out…for the sake of the Israeli cannabis patients.
According to research, “Migraine is highly prevalent, affecting 12% of the population, attacking up to 17% of women and 6% of men yearly. Among children, it tends to happen more in girls than boys.” A migraine can be very disabling and last from hours to two or three days. Migraines are considered to be the…
PTSD can have far-reaching effects on health, functionality as well as on quality of living, which is why having access to effective treatment is so important. If you are living with PTSD or are living with someone who has PTSD, you would have first-hand experience with how challenging it can be getting through life on…
Up until recently, lack of cannabis education meant that people were blissfully unaware of the fact that the plant is not limited to just one strain and, therefore, does not produce just one type of effect. Fortunately, agricultural experimentation has led to the market exploding in terms of strains that can satisfy everyone, from beginners…
Using cannabis to help combat anxiety is a tricky business. Studies have given us significant evidence that cannabis can be used to help cope with anxiety and because anxiety is so common, that’s an extremely welcome piece of information. In fact, 72% of daily cannabis users reported consumption to relax or relieve tension and 58%…
A cannabis compound that has been described as “cutting-edge” and “so elusive, laboratories often misidentify the compound as CBC (cannabichromene) or CBL (cannabicyclol)” is finally becoming better understood. Delta-10-tetrahydrocannabinol (delta-10 THC) is a need-to-know cannabinoid, and here’s why. What Is Delta-10 THC? Does Delta-10 Get You High? Is Delta-10 Safe? How Is Delta-10 Created? Is…
The anti-nausea and vomiting effects of cannabis have been known for several centuries. The evidence eventually became so compelling in clinical trials…
Experts are taking a bird’s eye view of an exciting and rapidly evolving area in cannabis research known as the endocannabinoidome (eCBome)….
Spliffs and joints, while similar, are different cannabis products rolled up in paper. If you are a seasoned cannabis smoker, you’re probably…